The Article related to acylaminoacylpiperidine preparation serine palmitoyltransferase spt inhibitor, pyrazolopyridinylbenzamide preparation serine palmitoyltransferase spt inhibitor, congenital disease sphingolipid accumulation treatment prevention acylaminoacylpiperidine preparation, cancer niemann pick disease treatment prevention acylaminoacylpiperidine preparation and other aspects.Recommanded Product: 7-Chloro-2,3-dihydro-1,8-naphthyridin-4(1H)-one
On October 27, 2016, Asano, Yasutomi; Kojima, Takuto; Kurasawa, Osamu; Wong, Tzu-Tshin; Hirata, Yasuhiro; Iwamura, Naoki; Saito, Bunnai; Tanaka, Yuta; Arai, Ryosuke; Imamura, Shinichi; Yonemori, Kazuko; Miyamoto, Yasufumi; Kitamura, Shuji; Sano, Osamu published a patent.Recommanded Product: 7-Chloro-2,3-dihydro-1,8-naphthyridin-4(1H)-one The title of the patent was Preparation of 1-acyl-4-acylaminopiperidine derivatives as serine palmitoyltransferase (SPT) inhibitors. And the patent contained the following:
The present invention relates to the title compounds I [ring Ar = each (un)substituted aromatic heterocyclyl or C6-14 aromatic hydrocarbyl; ring A = each (un)substituted C6-14 aromatic hydrocarbyl or heterocyclyl; R1 = each (un)substituted C6-14 aryl, C3-10 cycloalkyl, or heterocyclyl; when R1 is (un)substituted heterocyclyl, R1 = Q or Q1; ring B = (un)substituted heterocyclyl; ring D = (un)substituted N-containing heterocyclyl; R2 = H or R1 and R2 are bonded together to form (un)substituted 5- or 6-membered aromatic heterocyclyl or (un)substituted benzene ring] or salts thereof. These compounds are serine palmitoyltransferase (SPT) inhibitors and potentially useful for treating or preventing SPT-related disease including congenital disease accompanied by sphingolipid accumulation, cancer, and Niemann-Pick disease in mammals. Thus, 188 mg 2-chlorobenzoyl chloride was gradually added to a solution of 283 mg (7-amino-2-methyl-2,5,6,7-tetrahydro-4H-pyrazolo[4,3-b]pyridin-4-yl)(3,4-dimethoxyphenyl)methanone and 270 mg Et3N in 5 mL CH2Cl2 under ice-cooling and the resulting mixture was stirred at room temperature for 1 h to give, after workup and silica gel chromatog., 2-chloro-N-(4-(3,4-dimethoxybenzoyl)-2-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-b]pyridin-7-yl)benzamide (II). II at 1 μM inhibited 91% human serine palmitoyltransferase (SPT). A capsule and a tablet formulation containing II were described. The experimental process involved the reaction of 7-Chloro-2,3-dihydro-1,8-naphthyridin-4(1H)-one(cas: 76629-10-2).Recommanded Product: 7-Chloro-2,3-dihydro-1,8-naphthyridin-4(1H)-one
The Article related to acylaminoacylpiperidine preparation serine palmitoyltransferase spt inhibitor, pyrazolopyridinylbenzamide preparation serine palmitoyltransferase spt inhibitor, congenital disease sphingolipid accumulation treatment prevention acylaminoacylpiperidine preparation, cancer niemann pick disease treatment prevention acylaminoacylpiperidine preparation and other aspects.Recommanded Product: 7-Chloro-2,3-dihydro-1,8-naphthyridin-4(1H)-one
Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem